Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves pharmaceutical and biotechnology, agricultural and chemical, life science and veterinary medicine, and medical device companies; and contract research and contract manufacturing organizations, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone781-222-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.86 billion
Profitability
Miscellaneous
Employees11,800
OptionableOptionable
Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions
What is Charles River Laboratories Intl.'s stock symbol?
Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."
How will Charles River Laboratories Intl.'s stock buyback program work?
Charles River Laboratories Intl. declared that its board has authorized a share repurchase plan on Sunday, June 4th 2017, which permits the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.
How were Charles River Laboratories Intl.'s earnings last quarter?
Charles River Laboratories Intl. Inc (NYSE:CRL) issued its earnings results on Wednesday, November, 7th. The medical research company reported $1.53 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.38 by $0.15. The medical research company had revenue of $585.30 million for the quarter, compared to the consensus estimate of $567.58 million. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The business's revenue for the quarter was up 26.1% on a year-over-year basis. During the same quarter last year, the company earned $1.30 EPS. View Charles River Laboratories Intl.'s Earnings History.
When is Charles River Laboratories Intl.'s next earnings date?
How can I listen to Charles River Laboratories Intl.'s earnings call?
Charles River Laboratories Intl. will be holding an earnings conference call on Wednesday, February 13th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?
Charles River Laboratories Intl. updated its FY18 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of $5.87-5.97 for the period, compared to the Thomson Reuters consensus estimate of $5.91. The company issued revenue guidance of $2.25-2.27 billion, compared to the consensus revenue estimate of $2.23 billion.
What price target have analysts set for CRL?
15 analysts have issued 12 month price objectives for Charles River Laboratories Intl.'s shares. Their predictions range from $115.00 to $150.00. On average, they expect Charles River Laboratories Intl.'s stock price to reach $134.2143 in the next twelve months. This suggests a possible upside of 12.6% from the stock's current price. View Analyst Price Targets for Charles River Laboratories Intl..
What is the consensus analysts' recommendation for Charles River Laboratories Intl.?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..
Has Charles River Laboratories Intl. been receiving favorable news coverage?
News headlines about CRL stock have been trending very positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Charles River Laboratories Intl. earned a news impact score of 3.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are some of Charles River Laboratories Intl.'s key competitors?
Some companies that are related to Charles River Laboratories Intl. include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX) and Dyadic International (DYAI).
Who are Charles River Laboratories Intl.'s key executives?
Charles River Laboratories Intl.'s management team includes the folowing people:
- Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
- Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
- Mr. David P. Johst, Chief Admin. Officer, Corp. Exec. VP of HR, Gen. Counsel & Corp. Sec. (Age 57)
- Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
- Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)
Who are Charles River Laboratories Intl.'s major shareholders?
Charles River Laboratories Intl.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (0.38%), Retirement Systems of Alabama (0.30%), BTIM Corp. (0.30%), Personal Capital Advisors Corp (0.28%), National Investment Services Inc. WI (0.03%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Jason Wesley Scharfe, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..
Which institutional investors are selling Charles River Laboratories Intl. stock?
CRL stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, New England Research & Management Inc., BTIM Corp., Private Trust Co. NA, Oakbrook Investments LLC, National Investment Services Inc. WI and Louisiana State Employees Retirement System. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include Birgit Girshick, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..
Which institutional investors are buying Charles River Laboratories Intl. stock?
CRL stock was bought by a variety of institutional investors in the last quarter, including Highland Capital Management LLC, Fox Run Management L.L.C., CX Institutional, Personal Capital Advisors Corp, Meeder Asset Management Inc., Nisa Investment Advisors LLC, Retirement Systems of Alabama and Cardinal Capital Management. Company insiders that have bought Charles River Laboratories Intl. stock in the last two years include Bradley Nixon Scharfe and Jason Wesley Scharfe. View Insider Buying and Selling for Charles River Laboratories Intl..
How do I buy shares of Charles River Laboratories Intl.?
Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Charles River Laboratories Intl.'s stock price today?
One share of CRL stock can currently be purchased for approximately $119.21.
How big of a company is Charles River Laboratories Intl.?
Charles River Laboratories Intl. has a market capitalization of $5.73 billion and generates $1.86 billion in revenue each year. The medical research company earns $123.35 million in net income (profit) each year or $5.27 on an earnings per share basis. Charles River Laboratories Intl. employs 11,800 workers across the globe.
What is Charles River Laboratories Intl.'s official website?
How can I contact Charles River Laboratories Intl.?
Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]
MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
